Division of Dermatology, Department of Medicine, University of Hong Kong, Pokfulam, Hong Kong, China
CK Yeung ( 楊志強 ) MBBS, MRCP(UK), FHKAM
HHL Chan ( 陳衍里 ) MD(Lond), FRCP(Lond, Edin, Glasg), FHKAM
Division of Dermatology, Departments of Medicine and Therapeutics and Paediatrics, Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China
HHL Chan ( 陳衍里 ) MD(Lond), FRCP(Lond, Edin, Glasg), FHKAM
Correspondence to: Dr HHL Chan
Received June 7, 2007
Significant progress has been made in the understanding of the pathogenesis of atopic dermatitis but the cure remains elusive. The management strategy is therefore to reduce the disease exacerbation and produce comfort for affected children and their families. Thorough clinical assessment helps to guide the education process which is an essential part of management. Use of topical corticosteroids and emollients remain the first line management together with avoidance of triggers. The topical immunomodulating agents, tacrolimus and pimecrolimus have broadened the armamentarium in the management of atopic dermatitis. Use of systemic immunosuppressants is now proved to be safe and effective for refractory atopic dermatitis provided that proper ways of monitoring side effects are adopted. Novel management approach, such as probiotics, has evolved from advances in our understanding of the pathobiology of this common skin disease.